X4 Pharmaceuticals, Inc. XFOR
3.12 USD -0.05 (-1.58%)
At closeNov 13, 2026, 4:00 PM EST
3.12 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
2.98 Day range 3.20
2.43 52-week range 4.83
- YTD
- -22.00%
- 1 year
- -16.35%
News
benzinga.com X4 Pharmaceuticals Q3 EPS $(0.16) Beats $(0.19) Estimate, Sales $2.879M Beat $2.300M Estimate X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 76.81 percent increase over losses of…
benzinga.com Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading…
benzinga.com X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of…- benzinga.com Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11 Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.
benzinga.com Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12 Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Outperform rating and announces Price Target of $12.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com X4 Pharmaceuticals Q1 EPS $(0.16) Beats $(0.20) Estimate, Sales $2.708M Miss $3.200M Estimate X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 500 percent decrease over earnings of…- benzinga.com X4 Pharma Says EC Grants Marketing Authorization For XOLREMDI Capsules For Treatment Of Patients With WHIM Syndrome In EU - European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia -BOSTON, April 29,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com X4 Pharmaceuticals Q4 EPS $(0.22) Beats $(0.38) Estimate, Sales $2.568M Beat $1.733M Estimate X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 96.26 percent increase over losses of…
- benzinga.com Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12 Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and announces Price Target of $12.
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday - benzinga.com Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10 Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.
- benzinga.com HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $3.5 to $5.
- benzinga.com X4 Pharmaceuticals Q3 EPS $(0.69) Beats $(0.82) Estimate, Sales $1.765M Miss $1.901M Estimate X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.82) by 15.85 percent. This is a 87.41 percent increase over losses of…
- benzinga.com X4 Pharmaceuticals Prices $135M Public Offering Of 45.86M Common Shares At $2.90 Each To Advance Phase 3 Rare Disease Program And, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded…
- benzinga.com X4 Pharmaceuticals Launches Of An Underwritten Public Offering Of Its Common Stock; No Financial Terms Disclosed X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improve the lives of people with rare hematology diseases, today announced that it has commenced an underwritten public…
benzinga.com X4 Pharmaceuticals Announces Strategic Restructuring With 50% Workforce Reduction Expected To Deliver $13M Annualized Cost Savings Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13MJohn Volpone appointed Chief Operating Officer, in…- benzinga.com Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9 Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $3.5 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $7 to $3.5.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com X4 Pharmaceuticals Announced Private Placement In Public Equity Financing Of Approximately $60M $60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise AssociatesNewly appointed board and management team includes Dr. Adam Craig as Executive Chairman,…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com X4 Pharmaceuticals Enters Purchase Agreement With Lincoln Park; Can Sell Up To $40M In Stock https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000162828025032627/xfor-20250623.htm
- benzinga.com HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $1.5 to $7.
- benzinga.com Earnings Scheduled For May 1, 2025
- benzinga.com Earnings Preview For X4 Pharmaceuticals
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In April 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views
- benzinga.com HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains $1.5 price target.
- benzinga.com Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $3 Price Target Cantor Fitzgerald analyst Kristen Kluska reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight and maintains $3 price target.
- benzinga.com X4 Pharmaceuticals Q4 2024 GAAP EPS $(0.20) Misses $(0.17) Estimate, Sales $1.43M Beat $1.04M Estimate X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 100 percent decrease over losses of…
- benzinga.com Earnings Scheduled For March 25, 2025
- benzinga.com HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains $1.5 price target.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com X4 Pharmaceuticals Cuts Workforce by 30% to Focus on Mavorixafor for Chronic Neutropenia, Scales Back Research to Prioritize Rare Disease Treatments X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, announced today a restructuring of its workforce and capital spending to…
benzinga.com Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - benzinga.com HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains $1.5 price target.
- benzinga.com X4 Pharmaceuticals Secures Licensing Deal With Norgine To Bring Mavorixafor To Europe, Australia, And New Zealand; Total Deal Value Could Exceed €254M X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the…
- benzinga.com X4 Pharmaceuticals To Present Trial-In-Progress Poster On Phase 3 Study Of Mavorixafor In Chronic Neutropenia At 66th ASH Annual Meeting & Exposition X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced its upcoming presentations at the 66th American Society of…